Protein A compositions and methods of use
View Patent ↗Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg.
1. A method for treating psoriasis in a subject with or at risk of psoriasis, comprising administering to the subject a monomeric protein A (PA) composition comprising an effective amount of protein A (PA), wherein the PA in the composition consists of monomeric protein A (PA) sufficient to treat the psoriasis.
2. A method for treating scleroderma in a subject with or at risk of scleroderma, comprising administering to the subject a monomeric protein A (PA) composition comprising an effective amount of protein A (PA), wherein the PA in the composition consists of monomeric protein A (PA) sufficient to treat the scleroderma.
3. A method for reducing an inflammatory response in a subject caused by psoriasis or scleroderma, comprising administering to the subject a monomeric protein A (PA) composition comprising an effective amount of protein A (PA), wherein the PA in the composition consists of monomeric protein A (PA) sufficient to reduce an inflammatory response caused by psoriasis or scleroderma.
4. The method of claim 3 , wherein the inflammatory response is chronic or acute.
5. A method for treating inflammation in a subject caused by psoriasis or scleroderma, comprising administering to the subject a monomeric protein A (PA) composition comprising an effective amount of protein A (PA), wherein the PA in the composition consists of monomeric protein A (PA) sufficient to reduce the inflammation caused by psoriasis or scleroderma.
6. The method of claim 5 , wherein the inflammation is chronic or acute.
7. The method of claim 1 , wherein the method results in a reduction in severity of a symptom of psoriasis.
8. The method of claim 2 , wherein the method results in a reduction in severity of a symptom of scleroderma.
9. The method of claim 3 , wherein the method results in a reduction in severity of a symptom of the inflammatory response.
10. The method of claim 5 , wherein the method results in a reduction in severity of inflammation.
11. The method of claim 7 , wherein the symptom comprises swelling, pain, skeletal joint stiffness, or tissue or cell damage.
12. The method of claim 8 , wherein the symptom comprises swelling, pain, headache, fever, nausea, skeletal joint stiffness, or tissue or cell damage.
13. The method of claim 9 , wherein the symptom comprises swelling, pain, headache, fever, nausea, skeletal joint stiffness, or tissue or cell damage.
14. The method of claim 10 , wherein the symptom comprises swelling, pain, headache, fever, nausea, skeletal joint stiffness, or tissue or cell damage.
15. The method of claim 1 , wherein the subject is a human.
16. The method of claim 2 , wherein the subject is a human.
17. The method of claim 3 , wherein the subject is a human.
18. The method of claim 5 , wherein the subject is a human.
19. The method of claim 1 , 2 , 3 or 5 , wherein the monomeric PA composition is administered systemically.
20. The method of claim 1 , 2 , 3 or 5 , wherein the monomeric PA composition is administered locally.
21. The method of claim 1 , 2 , 3 or 5 , wherein the monomeric PA composition is administered intravenously, intramuscularly, intraperitoneally, intradermally, subcutaneously, intracavity, transdermally, parenterally, or transmucosally.